Displaying drugs 12851 - 12875 of 15432 in total
Lomvastomig
Lomvastomig is under investigation in clinical trial NCT04785820 (A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus).
Investigational
Matched Description: … Lomvastomig is under investigation in clinical trial NCT04785820 (A Study of Lomvastomig (RO7121661) and …
NAP-226-90
Experimental
Imolamine
Imolamine is a compound with a molecular weight of 260.33 g/mol with the formula diethyl[2-{5-imino-3-phenyl-4,5-dihydro-1,2,3-oxadiazol,-4-yl)ethyl]amine. It is developed under the brand name Coremax by Novartis consumer health SA.
Investigational
AKN-028
AKN-028 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
Bunaftine
Experimental
Br-Coeleneterazine
Experimental
Matched Iupac: … (2S,8S)-8-benzyl-2-[(4-bromophenyl)methyl]-2-hydroperoxy-6-(4-hydroxyphenyl)-2H,3H,7H,8H-imidazo[1,2- …
(3S)-3-(dioxidosulfanyl)-N-[(1Z)-3-oxoprop-1-en-1-yl]-4-(1H-1,2,3-triazol-1-yl)-D-valine
Experimental
Matched Iupac: … (1S)-1-carboxy-2-methyl-1-{[(1Z)-3-oxoprop-1-en-1-yl]amino}-3-(1H-1,2,3-triazol-1-yl)propane-2-sulfinate …
Implitapide
Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.
Investigational
Matched Iupac: … (2S)-2-cyclopentyl-2-[3-({2,4-dimethyl-9H-pyrido[2,3-b]indol-9-yl}methyl)phenyl]-N-[(1R)-2-hydroxy-1- …
Ranirestat
Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels. It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.
Investigational
Matched Iupac: … (3R)-2'-[(4-bromo-2-fluorophenyl)methyl]-2',3'-dihydro-1'H-spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine …
Matched Description: … Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21 …
Matched Description: … Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21 …
Hypothemycin
Experimental
Matched Iupac: … (2R,4R,6S,7S,9Z,12S)-6,7,16-trihydroxy-18-methoxy-12-methyl-3,13-dioxatricyclo[13.4.0.0^{2,4}]nonadeca …
Henagliflozin
Henagliflozin has been used in trials studying the treatment of Type 2 Diabetes.
Investigational
Matched Iupac: … (1R,2S,3S,4R,5R)-5-{4-chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl}-1-(hydroxymethyl)-6,8-dioxabicyclo …
PF-05180999
PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).
Investigational
Matched Iupac: … 2-{4-[4-(azetidin-1-yl)-7-methylimidazo[4,3-f][1,2,4]triazin-5-yl]-1-methyl-1H-pyrazol-5-yl}-5-(trifluoromethyl …
Petesicatib
Petesicatib is under investigation in clinical trial NCT02295332 (A Study of RG7625 in Healthy Volunteers).
Investigational
Matched Iupac: … (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)benzenesulfonyl]-1- …
Coronavirus-Like Particle COVID-19 Vaccine
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the...
Investigational
Matched Description: … The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec ... VLPs are thought to have multiple mechanisms involving the immune system which engage both humoral and ... A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity …
benzyl (2-oxopropyl)carbamate
Experimental
Bamethan
Experimental
Isobromindione
Experimental
ARC183
ARC183 is a DNA aptamer, which is a single-stranded DNA molecule consisting of 15 deoxynucleotides that forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity and specificity. The key
advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life,...
Investigational
Matched Description: … forms well-defined three-dimensional configuration, allowing it to bind to thrombin with high affinity and ... The key
advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short …
KAI-1455
KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and hip replacement and may protect against renal injury associated with contrast media. Several studies...
Investigational
Matched Description: … hip replacement and may protect against renal injury associated with contrast media. ... may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and …
LX-2931
Investigational
Minodronic acid
Investigational
Nesvacumab
Nesvacumab is under investigation in clinical trial NCT01997164 (Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)).
Investigational
Matched Description: … Nesvacumab is under investigation in clinical trial NCT01997164 (Study of Intravitreal (IVT) REGN910-3 and …
Displaying drugs 12851 - 12875 of 15432 in total